Taking on-board the Alexion acquisition
21/07/21 -"AstraZeneca has completed the acquisition of Alexion Pharmaceuticals (US rare diseases specialist). Given that rare diseases are a high-growth and attractive margin area (even ahead of oncology), ..."
Pages
70
Language
English
Published on
21/07/21
You may also be interested by these reports :
06/11/26
Novonesis delivered an in-line Q3 26, with revenue and adjusted EBITDA marginally ahead of consensus. Food & Beverages (F&B) accelerated to 14%, ...
05/11/26
The Q3 qualitative update did not materially change the full-year outlook, as Branded’s strong momentum made up for the relative weakness in ...
04/11/26
The weight-loss Wegovy pill drove the Q3 beat, while most key drugs suffered from pricing and competitive pressures. With the previous outlook being ...
04/11/26
“If a man knows not to which port he sails, no wind is favourable.” The Roman philosopher Seneca’s line may strike a chord with GSK’s (BUY; UK) ...